Biotech · Public company · New Haven, CT, US
BioXcel Therapeutics, Inc.
Ticker BTAIQ · SEC CIK 0001720893
Track this companyFree. Adds BioXcel Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials204 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- BXCL501Phase 3 · AgitationClinicalTrials.gov · fetched Nov 12, 2026
- BXCL501Phase 3 · Agitation,PsychomotorClinicalTrials.gov · fetched Nov 12, 2026
- Sublingual film containing dexmedetomidine (BXCL501)Phase 3 · AgitationClinicalTrials.gov · fetched Nov 12, 2026
- Sublingual film containing Dexmedetomidine (BXCL501)Phase 3 · Agitation Associated With Bipolar DisorderClinicalTrials.gov · fetched Nov 12, 2026
- BXCL501 Sublingual FilmPhase 2 · Bipolar I DisorderClinicalTrials.gov · fetched Nov 12, 2026
- DexmedetomidinePhase 2 · Opioid WithdrawalClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Sublingual film containing DexmedetomidinePhase 2 · Agitation,PsychomotorClinicalTrials.gov · fetched Nov 12, 2026
- TalabostatPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- BXCL501 120 MicrogramsPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- BXCL501 60 MicrogramsPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- BXCL501 80 MicrogramsPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Sublingual film containing BXCL501 (Dexmedetomidine)Phase 1 · AgitationClinicalTrials.gov · fetched Nov 12, 2026
- Talabostat MesylatePhase 1 · Cancer of PancreasClinicalTrials.gov · fetched Nov 12, 2026
- Sublingual film containing IgalmiBipolar DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials20
- Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient StudyPHASE1 · RECRUITING · started Jul 28, 2025ClinicalTrials.gov NCT06335407 · fetched Nov 12, 2026
- Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderPHASE2 · COMPLETED · started Jun 19, 2025ClinicalTrials.gov NCT07116694 · fetched Nov 12, 2026
- Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderPHASE4 · COMPLETED · started Oct 2, 2023ClinicalTrials.gov NCT06041646 · fetched Nov 12, 2026
- BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal AdenocarcinomaPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 16, 2023ClinicalTrials.gov NCT05558982 · fetched Nov 12, 2026
- Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar DisorderPHASE4 · UNKNOWN · started Jul 1, 2023ClinicalTrials.gov NCT06093451 · fetched Nov 12, 2026
- Sublingual Dexmedetomidine for Treating Opioid WithdrawalPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 28, 2023ClinicalTrials.gov NCT05712707 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)PHASE3 · TERMINATED · started Dec 5, 2022ClinicalTrials.gov NCT05665088 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)PHASE3 · COMPLETED · started Nov 21, 2022ClinicalTrials.gov NCT05658510 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)PHASE3 · COMPLETED · started Apr 27, 2022ClinicalTrials.gov NCT05271552 · fetched Nov 12, 2026
- An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaPHASE2 · TERMINATED · started Feb 8, 2022ClinicalTrials.gov NCT05276830 · fetched Nov 12, 2026
- Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction StudyPHASE1 · COMPLETED · started Nov 9, 2021ClinicalTrials.gov NCT04827056 · fetched Nov 12, 2026
- Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderPHASE1 · RECRUITING · started Aug 27, 2021ClinicalTrials.gov NCT05025605 · fetched Nov 12, 2026
- Study of BXCL501 In Agitation Associated With Delirium in ICU PatientsPHASE2 · WITHDRAWN · started Feb 23, 2021ClinicalTrials.gov NCT05313386 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid WithdrawalPHASE1_PHASE2 · COMPLETED · started Jun 9, 2020ClinicalTrials.gov NCT04470050 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderPHASE3 · COMPLETED · started Feb 24, 2020ClinicalTrials.gov NCT04276883 · fetched Nov 12, 2026
- Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaPHASE3 · COMPLETED · started Jan 24, 2020ClinicalTrials.gov NCT04268303 · fetched Nov 12, 2026
- Sub-Lingual Dexmedetomidine in Agitation Associated With DementiaPHASE1_PHASE2 · COMPLETED · started Dec 27, 2019ClinicalTrials.gov NCT04251910 · fetched Nov 12, 2026
- A Pilot Study of BXCL701 in Patients With Pancreatic CancerEARLY_PHASE1 · WITHDRAWN · started Oct 15, 2019ClinicalTrials.gov NCT04123574 · fetched Nov 12, 2026
- A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma PhenotypePHASE1_PHASE2 · COMPLETED · started Jun 10, 2019ClinicalTrials.gov NCT03910660 · fetched Nov 12, 2026
- Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaPHASE1 · COMPLETED · started May 22, 2019ClinicalTrials.gov NCT04010305 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 1, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 25, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 24, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 17, 2026 · fetched Nov 12, 2026